Guaranteed adherence. Better outcomes.™
Through miniaturized, ultra-long-acting biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.
Addressing the biggest challenges in chronic disease treatment – medication non-adherence and tolerability.
An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.
Watch our CEO, Dr. Adam Mendelsohn, introduce our revolutionary approach to improve chronic disease treatment with miniature, ultra long-acting drug implants.Our long-term solution for life-long conditions.
Our Lead Drug Candidate: NPM-139
GLP-1 (semaglutide) Implant for Chronic Weight Management
NPM-139 is a miniature, subdermal semaglutide implant under development for chronic weight management in patients with obesity or overweight, designed for once- or twice-yearly administration. The implant is designed to be inserted under the skin during an outpatient procedure and to provide steady doses of medication. SLIM-1™, the Phase 1 clinical trial of NPM-139, generated positive safety and tolerability data and encouraging pharmacokinetics for a low-dose NPM-139 implant compared with the 0.25 mg/week starting dose of Wegovy® (n=10 per group). Treatment-related adverse events were reported in 0 of 10 subjects in the NPM-139 group and 5 of 10 subjects in the Wegovy group. Weight loss was comparable between the two groups. These SLIM-1 results, coupled with the previously reported preclinical weight loss data, support advancing NPM-139 toward SLIM-2™, a planned Phase 2 dose-ranging weight maintenance trial.
Also in Development: NPM-133
GLP-1 (semaglutide) Implant for Type 2 Diabetes
NPM-133 is a miniature, subdermal semaglutide implant under development to treat patients with type 2 diabetes. Like NPM-139, the implant is designed to be inserted under the skin during an outpatient procedure and to provide steady doses of medication for up to six months. Data from the SLIM-1 trial are also expected to inform the NPM-133 program.
Wegovy® is a registered trademark of Novo Nordisk A/S.
